Setmelanotide

What is Setmelanotide?

Setmelanotide is a cyclic peptide that activates the melanocortin-4 receptor (MC4R), a key regulator of appetite and energy balance. It is FDA-approved for chronic weight management in patients with specific rare genetic obesity conditions (POMC, PCSK1, or LEPR deficiency), Bardet-Biedl syndrome (BBS), and — as of March 2026 — acquired hypothalamic obesity in adults and pediatric patients aged 4 and older. It represents one of the first precision medicine approaches to obesity treatment, with its most recent approval making it the first and only approved therapy for acquired hypothalamic obesity.

What Setmelanotide Is Investigated For

Setmelanotide is investigated and FDA-approved for rare MC4R-pathway obesity — POMC, PCSK1, and LEPR deficiency, plus Bardet-Biedl syndrome — and, as of March 19, 2026, for acquired hypothalamic obesity in patients aged 4 and older. The strongest evidence is in exactly these populations, where 52-week trials produced mean weight loss of about 23% in POMC/PCSK1 deficiency and about 10% in LEPR deficiency (single-arm trials, not placebo-corrected), and a mean BMI reduction of about 8% in BBS. The March 2026 acquired-HO approval was supported by the pivotal Phase 3 TRANSCEND trial (n=142): setmelanotide produced a −15.8% BMI reduction vs. a +2.6% increase on placebo at 52 weeks — an 18.4% placebo-adjusted effect (the 120-patient primary cohort, published in the New England Journal of Medicine in July 2026, showed −16.5% versus +3.3%), in a disease (hypothalamic injury-driven obesity, ~10,000 US patients) with no previously approved therapy. The biology is precision-medicine clean in each approved population: the leptin-melanocortin satiety pathway is disrupted upstream (monogenic) or at the hypothalamic site (acquired HO), and setmelanotide restores the missing MC4R signal. The honest caveats are narrow but important. The drug is not effective for general polygenic obesity, and the side-effect profile (skin darkening in about two-thirds of patients, labeled depression and suicidal ideation warnings, sexual adverse events) is not justified outside approved indications. Long-term cardiovascular, neuropsychiatric, and pediatric-development safety beyond trial follow-up remains under active surveillance, and combination regimens with GLP-1 agonists are unstudied.

History & Discovery

Setmelanotide emerged from research at Ipsen and was acquired and developed by Rhythm Pharmaceuticals, a Boston biotech founded specifically to advance precision treatments for rare melanocortin-pathway obesity disorders. The molecule's design — a cyclic octapeptide with high MC4R selectivity relative to first-generation tool compounds like Melanotan II — was driven by decades of academic genetics work establishing that loss-of-function mutations in POMC, PCSK1, LEPR, and MC4R itself produce severe early-onset obesity by disrupting the leptin-melanocortin satiety pathway in the hypothalamus. The therapeutic hypothesis was straightforward: in patients whose upstream signaling is broken but whose downstream MC4R is intact, providing an exogenous MC4R agonist could restore the missing 'fullness' signal. Rhythm advanced setmelanotide through Phase 1 and 2 trials in MC4R-pathway obesity in the mid-2010s, with proof-of-concept results in POMC deficiency (two patients, NEJM 2016) and LEPR deficiency (three patients, Nature Medicine 2018) demonstrating dramatic weight loss in patients who had been unable to lose weight through any conventional intervention. Pivotal Phase 3 single-arm trials in POMC, PCSK1, and LEPR deficiency formed the basis for the November 2020 FDA approval of Imcivree — a notable approval because the indicated population is vanishingly small (low thousands of patients globally) and because the trials were single-arm and open-label, with only a short blinded placebo-withdrawal period — a design suited to the rarity of the disease. In June 2022, FDA expanded the indication to include Bardet-Biedl syndrome (BBS) following a randomized Phase 3 trial showing significant weight reduction. In December 2024 the FDA extended the BBS and POMC/PCSK1/LEPR indications down to age 2, based on the 12-patient VENTURE trial. On March 19, 2026, the FDA approved setmelanotide for a fundamentally different population: acquired hypothalamic obesity in adults and pediatric patients aged 4 and older. Unlike the prior monogenic indications, acquired HO is not a germline genetic disease — it results from injury (surgery, radiation, tumor) to the hypothalamic appetite-regulation centers, most often after childhood craniopharyngioma resection. Rhythm estimates approximately 10,000 US patients with acquired HO. The approval rested on the pivotal Phase 3 TRANSCEND trial (n=142), which showed a −15.8% BMI reduction on setmelanotide versus +2.6% on placebo at 52 weeks — an 18.4% placebo-adjusted effect. This made Imcivree the first and only approved therapy for acquired hypothalamic obesity. The 120-patient primary cohort was published in the New England Journal of Medicine in July 2026 (BMI −16.5% on setmelanotide versus +3.3% on placebo). In Europe, a positive CHMP opinion on 26 March 2026 was followed by European Commission authorization on 1 May 2026, the UK MHRA added the indication on 11 August 2026, and Japan approved it on 24 August 2026. The acquired-HO approval has also opened an adjacent frontier: MC4R agonism is now being explored in other syndromic forms of hypothalamic obesity, including ROHHAD syndrome (rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation), where a 2026 single-patient case report described off-label setmelanotide producing 28% weight loss in a boy with ROHHAD, followed by 10% regain within 3 months after insurance stopped covering it. Not every expansion has worked: in March 2026 the Phase 3 EMANATE trial in people carrying a single (heterozygous) variant in POMC/PCSK1, LEPR, SRC1, or SH2B1 missed its primary endpoint in all four substudies. Imcivree is one of the clearer examples of mechanism-targeted obesity pharmacology in the modern era, now spanning both genetic and acquired disruption of the same leptin-melanocortin pathway.

How It Works

In certain rare genetic conditions, or after injury to the hypothalamus, the brain's appetite-control pathway is broken. Setmelanotide restores the missing signal by directly activating the MC4 receptor, which tells the brain 'you're full' — something these patients' bodies cannot do on their own.

Setmelanotide is a cyclic octapeptide that selectively agonizes MC4R in the hypothalamic paraventricular nucleus, restoring the leptin-POMC-MC4R signaling cascade that is disrupted in POMC, PCSK1, or LEPR deficiency, impaired in BBS, and damaged by hypothalamic injury in acquired hypothalamic obesity. MC4R activation reduces food intake and increases energy expenditure; in a 72-hour study in people with common obesity, it raised resting energy expenditure by about 6% (111 kcal a day). Setmelanotide has about 20-fold less activity at MC1R and MC3R than at MC4R. The skin hyperpigmentation side effect results from cross-reactivity with MC1R on melanocytes.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Setmelanotide:

• 01Heterozygous variant carriers — the Phase 3 EMANATE trial found no significant BMI benefit over placebo at 52 weeks in people with one copy of a POMC/PCSK1, LEPR, SRC1, or SH2B1 variant (placebo-adjusted changes of −1.7% to −4.3%). Rhythm plans to study POMC and SRC1 further with next-generation agonists, so whether any subgroup benefits remains open.
• 02Hormonal effects beyond weight — a 58-patient BBS cohort saw rises in reproductive hormones and IGF-1 and a fall in TSH within 6 months, partly independent of weight loss; the long-term clinical meaning is unknown.
• 03Adrenal and sodium safety in acquired hypothalamic obesity — serious acute adrenal insufficiency occurred in 5% of treated patients versus none on placebo, and serious adverse events overall were 28% versus 8% in the NEJM cohort. Why this happens, and which patients are most at risk, is not yet defined.
• 04Polygenic obesity efficacy — setmelanotide has been studied almost exclusively in monogenic and BBS populations; whether MC4R agonism produces meaningful weight loss in the much larger common-obesity population is unresolved, with mixed signals from earlier exploratory studies.
• 05Long-term cardiovascular and metabolic outcomes — a 72-hour crossover study found no adverse effect of setmelanotide on heart rate or blood pressure, and the label reports numeric blood-pressure improvements alongside weight loss, but no trial has measured hard cardiovascular outcomes over years of continuous use.
• 06Depression and suicidality signal — the mechanism behind the labeled neuropsychiatric warning is not fully characterized, and predictors of which patients are at higher risk are not defined.
• 07Combination regimens — setmelanotide plus GLP-1 receptor agonists or other weight-loss agents has not been evaluated in adequately powered trials; mechanistic complementarity is plausible but unproven.
• 08Pediatric long-term safety — approval down to age 2 (monogenic) and age 4 (acquired HO) was supported by trial data with limited follow-up; long-term effects on growth, puberty, bone development, and neurodevelopment require ongoing surveillance.
• 09Real-world acquired-HO response — the TRANSCEND trial population had a mean baseline BMI well above the general obesity average and a defined hypothalamic-injury phenotype; how the effect translates across milder phenotypes, different injury etiologies (tumor vs. radiation vs. surgical), and longer time horizons is still accruing.

Forms & Administration

Once-daily subcutaneous injection at the start of the day, drawn from a 10 mg/mL multiple-dose vial with a 1-mL syringe and a 28- or 29-gauge needle. The starting dose depends on indication and age: 0.5 mg for acquired hypothalamic obesity at any age from 4 up; 2 mg for ages 12 and older with BBS or POMC/PCSK1/LEPR deficiency; 1 mg for ages 6 to 11; and 0.5 mg for ages 2 to 5. Doses are raised in 2-week steps toward 3 mg daily maintenance for ages 6 and older. All injectable peptides should only be administered under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Imcivree is FDA-approved only to reduce excess body weight in patients aged 4 and older with acquired hypothalamic obesity, and in patients aged 2 and older with Bardet-Biedl syndrome or with POMC, PCSK1, or LEPR deficiency confirmed by genetic testing. Use for general (polygenic) obesity is not approved, has not been adequately studied, and should not be expected to produce the responses seen in MC4R-pathway disease.

Timeline of Effects

Common Questions

Who Setmelanotide Is NOT For

Drug & Supplement Interactions

Setmelanotide is metabolized through proteolytic peptidase pathways rather than cytochrome P450, so classical CYP-mediated drug interactions are minimal. Laboratory testing suggests a low potential for drug interactions through CYP enzymes, transporters, or protein binding, but no clinical drug-interaction studies have been done. The most relevant interaction concerns are pharmacodynamic rather than pharmacokinetic. Co-administration with other agents that modulate mood — SSRIs, SNRIs, mood stabilizers — does not have a documented PK interaction but warrants additional monitoring given the labeled depression and suicidal ideation warning. Co-administration with other weight-loss agents (semaglutide, tirzepatide, phentermine) has not been studied and is not part of any approved regimen; combining is off-label and not supported by data. In acquired hypothalamic obesity with central diabetes insipidus, doses of diabetes insipidus medication may need adjusting, guided by sodium monitoring. For patients receiving therapies with skin or pigmentary effects (PUVA, hydroxychloroquine, certain chemotherapeutics), the additive cosmetic effect of setmelanotide-induced hyperpigmentation should be discussed before initiation. As with any chronic injectable specialty therapy, patients should disclose all prescription, OTC, and supplement use to their prescriber.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions